De Coninck Stien, Berx Geert, Taghon Tom, Van Vlierberghe Pieter, Goossens Steven
Department of Biomolecular Medicine, Ghent University, Ghent, Belgium; Cancer Research Institute Ghent (CRIG), Ghent, Belgium.
Cancer Research Institute Ghent (CRIG), Ghent, Belgium; Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium.
Adv Biol Regul. 2019 Dec;74:100639. doi: 10.1016/j.jbior.2019.100639. Epub 2019 Jul 27.
The identification of the rare but recurrent t(2; 14)(q22; q32) translocation involving the ZEB2 locus in T-cell acute lymphoblastic leukemia, suggested that ZEB2 is an oncogenic driver of this high-risk subtype of leukemia. ZEB2, a zinc finger E-box homeobox binding transcription factor, is a master regulator of cellular plasticity and its expression is correlated with poor overall survival of cancer patients. Recent loss- and gain-of-function in the mouse revealed important roles of ZEB2 during different stages of hematopoiesis, including the T-cell lineage. Here, we summarize the roles of ZEB2 in T-cells, their development, and malignant transformation to T-ALL.
在T细胞急性淋巴细胞白血病中发现罕见但反复出现的涉及ZEB2基因座的t(2; 14)(q22; q32)易位,提示ZEB2是这种高危白血病亚型的致癌驱动因子。ZEB2是一种锌指E盒同源框结合转录因子,是细胞可塑性的主要调节因子,其表达与癌症患者总体生存率低相关。最近在小鼠中的功能丧失和功能获得研究揭示了ZEB2在造血不同阶段(包括T细胞谱系)的重要作用。在这里,我们总结了ZEB2在T细胞、其发育以及向T-ALL恶性转化中的作用。